Amsilk's E.coli-made Biosteel fibre is being developed in partnerships to develop running ultra-lightweigt running shoes and composites with high mechanical robustness for use in the aerospace industry. © AMSilk GmbH

AMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.

Thanks to a grant by Germany's €45m funding programme for clinical COVID-19 therapeutics set up in January 2021, CORAT Therapeutics got money to start their Phase I/II programme with COR-101. In May the funding programme will be upgraded by €300m - a model for the EU? © NIAID

Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.

© Pixabay.com

International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.

© UNICEF

The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.

© Oculis SA

Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.

Belgium-based Celyad has had a new CMO since April: Dr Charles Morris.

© Mogrifiy

Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.

© Triggermouse/pixabay.com

Moderna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.

Manual and automated sample processing comparison for the EchoLUTION Viral RNA/DNA Swab Kit. (©BioEcho)

During the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.

© ADCendo Aps

Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.